An experimental device aimed at relieving chronic ocular surface pain (COSP) has shown promising results in an Australian clinical trial.
The study involved 31 Australian patients and tested a device called ETX-4143, developed by EyeCool Therapeutics, a company based in Cambridge, Massachusetts. The research was a pilot-stage, randomised, double-masked study designed to assess the safety and effectiveness of the device.
Initial results were presented in February at the American European Congress of Ophthalmic Surgery Winter Symposium, held in Aspen, Colorado.
According to a media release from EyeCool Therapeutics, ETX-4143 works by gently cooling the surface of each eye for four minutes. The cooling targets the myelinated long ciliary nerves, which are known to play a role in chronic eye pain, especially in patients with dry eye disease.
The company reported that many patients experienced immediate relief, with the effects continuing to improve over several weeks. A significant reduction in the severity of eye pain was measured using a patient-reported outcome tool specifically designed for COSP.
EyeCool Therapeutics described the results as statistically significant and said they provide early evidence that ETX-4143 could be a safe and effective treatment option for those suffering from persistent eye pain.
Related topics:
- BNP Secretary General Mirza Fakhrul Recovers After Eye Surgery in Thailand
- New CCOI CEO Malvina Eydelman Aims to Transform Global Eye Care Innovation
- Dr. Neda Shamie Highlights Game-Changing Advances in Pharmacological Presbyopia Treatments
